Project Grant R43DK121626

Federal Project Grant Award Summary Angiotensin Therapeutics Inc. received a $314,355 Project Grant awarded September 15, 2025, by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research and development of AGT001, a bioengineered soluble Angiotensin Converting Enzyme 2 (ACE2) therapeutic designed to prevent or attenuate delayed graft function (DGF) in...

This $1,488,899 Project Grant award was provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Young Therapeutics LLC, a pharmaceutical research and development company based in Pennsylvania. The funding supports the advanced development and validation of two proprietary compounds, YT-002 and YT-004, which target specific protein kinases to preserve myocardial tissue and cardiac function following myocardial infarction. The research aims to...

Grant Award Summary Angiotensin Therapeutics Inc. received a $591,488 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 15, 2025 through August 31, 2026. The company is conducting preclinical research to develop and evaluate AGT001, a bioengineered soluble Angiotensin-Converting Enzyme 2 (ACE2) therapeutic candidate designed to...

Grant Award Summary Brigham & Women's Hospital received a $387,968 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 15, 2025, through July 31, 2030. The award funds the RESTORE observational study, which investigates the interplay of inflammation, angiogenesis, and coronary microvascular perfusion in patients with advanced chronic kidney disease (CKD). The research examines how systemic...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $275,739 project grant under the Cardiovascular Diseases Research (CFDA 93.837) program to WR Biotech, LLC, a small disadvantaged business. The grant supports research on a novel technique called Improved Synchronization Modulation Electric Field (I-SMEF) to protect donor hearts and improve transplanted heart graft function during cold storage prior to heart transplantation in mice. The I-SMEF technique aims to maintain...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a $560,000 research initiative led by Baylor College of Medicine to develop a "triple gene therapy" treatment for ischemic heart failure. The goal is to leverage a combination of three experimental approaches - inducing cardiomyocyte proliferation, direct cardiac reprogramming of fibroblasts, and increasing angiogenesis - to synergistically regenerate...

This Project Grant award of $528,179, awarded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research conducted by the University of Miami to investigate reprogramming of monocytes to improve neovascularization in peripheral arterial disease and critical limb ischemia. The key objectives are to: 1) determine if extracellular vesicles mediate the systemic effects of monocyte reprogramming, and 2) investigate how reduced expression of the...

Grant Award Summary The University of North Texas Health Science Center at Fort Worth received a $532,177 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective July 1, 2025 through June 30, 2029. The research project investigates a novel inflammation pathway in diabetic kidney disease (DKD), the leading cause of end-stage renal disease. The study...

The National Heart, Lung, and Blood Institute (NHLBI) awarded Covenant Therapeutics LLC a $249,965 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) on September 10, 2023. The purpose of this grant is to further develop a novel therapeutic approach involving small peptide erythropoietin (EPO) analogs as an alternative to recombinant human EPO for the treatment of anemias, particularly those secondary to renal disease and malignancy. The key objectives are to optimize the lead...

Federal Project Grant Award Summary Regennova, Inc. received a $349,325 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective August 1, 2025, through July 31, 2027. The company is developing a novel oral therapeutic agent targeting the arginine-polyamine metabolic pathway as a treatment for autosomal dominant polycystic kidney disease (ADPKD), a...